Skip to main content
Top
Published in: Current HIV/AIDS Reports 2/2015

01-06-2015 | The Global Epidemic (SH Vermund, Section Editor)

Epidemiological Trends for HIV in Southern Africa: Implications for Reaching the Elimination Targets

Authors: Brian G. Williams, Eleanor Gouws, Pierre Somse, Mpho Mmelesi, Chibwe Lwamba, Trouble Chikoko, Erika Fazito, Mohamed Turay, Eva Kiwango, Pepukai Chikukwa, Henry Damisoni, Michael Gboun

Published in: Current HIV/AIDS Reports | Issue 2/2015

Login to get access

Abstract

Southern Africa is the region worst affected by HIV in the world and accounts for one third of the global burden of HIV. Achieving the UNAIDS 90-90-90 target by 2020 and ending the AIDS epidemic by 2030 depend on success in this region. We review epidemiological trends in each country in southern Africa with respect to the prevalence, incidence, mortality, coverage of anti-retroviral therapy (ART) and TB notification rates, to better understand progress in controlling HIV and TB and to determine what needs to be done to reach the UNAIDS targets. Significant progress has been made in controlling HIV. In all countries in the region, the prevalence of HIV in people not on ART, the incidence of HIV, AIDS-related mortality and, in most countries, TB notification rates, are falling. In some countries, the risk of infection began to fall before biomedical interventions such as ART became widely available as a result of effective prevention measures or people’s awareness of, and response to, the epidemic but the reasons for these declines remain uncertain. Some countries have achieved better levels of ART coverage than others, but all are in a position to reach the 2020 and 2030 targets if they accelerate the roll-out of ART and of targeted prevention efforts. Achieving the HIV treatment targets will further reduce the incidence of HIV-related TB, but efforts to control TB in HIV-negative people must be improved and strengthened.
Appendix
Available only for authorised users
Literature
3.
go back to reference Department of International Economic and Social Affairs. World demographic estimates and projections, 1950–2025 United Nations, New York 1988. Department of International Economic and Social Affairs. World demographic estimates and projections, 1950–2025 United Nations, New York 1988.
7.
9.
go back to reference Williams BG, Granich R, De Cock K, Glaziou P, Sharma A, Dye C. Anti-retroviral therapy for the control of HIV-associated tuberculosis: modelling the potential effects in nine African countries. Proc Natl Acad Sci U S A. 2010;107:17853–4.CrossRef Williams BG, Granich R, De Cock K, Glaziou P, Sharma A, Dye C. Anti-retroviral therapy for the control of HIV-associated tuberculosis: modelling the potential effects in nine African countries. Proc Natl Acad Sci U S A. 2010;107:17853–4.CrossRef
11.
go back to reference Stover J, Brown T, Marston M. Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect. 2012;88 Suppl 2:i11–6.CrossRefPubMedCentralPubMed Stover J, Brown T, Marston M. Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect. 2012;88 Suppl 2:i11–6.CrossRefPubMedCentralPubMed
12.•
go back to reference Awad SF, Abu-Raddad LJ. Could there have been substantial declines in sexual risk behavior across sub-Saharan Africa in the mid-1990s? Epidemics. 2014;8:9–17. A similar analysis but with fewer countries and output variables. CrossRefPubMed Awad SF, Abu-Raddad LJ. Could there have been substantial declines in sexual risk behavior across sub-Saharan Africa in the mid-1990s? Epidemics. 2014;8:9–17. A similar analysis but with fewer countries and output variables. CrossRefPubMed
13.
go back to reference Halperin DT, Mugurungi O, Hallett TB, Muchini B, Campbell B, Magure T, et al. A surprising prevention success: why did the HIV epidemic decline in Zimbabwe? PLoS Med. 2011;8, e1000414.CrossRefPubMedCentralPubMed Halperin DT, Mugurungi O, Hallett TB, Muchini B, Campbell B, Magure T, et al. A surprising prevention success: why did the HIV epidemic decline in Zimbabwe? PLoS Med. 2011;8, e1000414.CrossRefPubMedCentralPubMed
14.
go back to reference Hargrove JW, Humphrey JH, Mahomva A, Williams BG, Chidawanyika H, Mutasa K, et al. Declining HIV prevalence and incidence in perinatal women in Harare, Zimbabwe. Epidemics. 2011;3:88–94.CrossRefPubMed Hargrove JW, Humphrey JH, Mahomva A, Williams BG, Chidawanyika H, Mutasa K, et al. Declining HIV prevalence and incidence in perinatal women in Harare, Zimbabwe. Epidemics. 2011;3:88–94.CrossRefPubMed
15.•
go back to reference Gregson S, Gonese E, Hallett TB, Taruberekera N, Hargrove JW, Lopman B, et al. HIV decline in Zimbabwe due to reductions in risky sex? Evidence from a comprehensive epidemiological review. Int J Epidemiol. 2010;39:1311–23. Attempt to explain the decline in the epidemic of HIV in Zimbabwe. CrossRefPubMedCentralPubMed Gregson S, Gonese E, Hallett TB, Taruberekera N, Hargrove JW, Lopman B, et al. HIV decline in Zimbabwe due to reductions in risky sex? Evidence from a comprehensive epidemiological review. Int J Epidemiol. 2010;39:1311–23. Attempt to explain the decline in the epidemic of HIV in Zimbabwe. CrossRefPubMedCentralPubMed
16.
go back to reference Robb M. RV217: The early capture HIV cohort study (ECHO). Prospective identification of HIV infection prior to acute viraemia among high-risk populations. Poster Abstract 404. Presented at the Keystone Symposium. Whistler, British Columbia, Canada (2011). Robb M. RV217: The early capture HIV cohort study (ECHO). Prospective identification of HIV infection prior to acute viraemia among high-risk populations. Poster Abstract 404. Presented at the Keystone Symposium. Whistler, British Columbia, Canada (2011).
17.
go back to reference Robb M. Viral dynamics and immune response in acute infection and their impact on viral set-point. In: Plenary session 02: a new look at the transmission event AIDS 2012 vaccine; Boston, 9–12 September 2012. Robb M. Viral dynamics and immune response in acute infection and their impact on viral set-point. In: Plenary session 02: a new look at the transmission event AIDS 2012 vaccine; Boston, 9–12 September 2012.
18.
go back to reference Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492–501.CrossRefPubMedCentralPubMed Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492–501.CrossRefPubMedCentralPubMed
19.
go back to reference Harington JS, McGlashan ND, Chelkowska EZ. A century of migrant labour in the gold mines of South Africa. J S Afr Inst Min Metall. 2004; 65–71. Harington JS, McGlashan ND, Chelkowska EZ. A century of migrant labour in the gold mines of South Africa. J S Afr Inst Min Metall. 2004; 65–71.
20.
go back to reference Brink B, Clausen L. The acquired immune deficiency syndrome. J Mine Med Off Assoc. 1987;63:10–7. Brink B, Clausen L. The acquired immune deficiency syndrome. J Mine Med Off Assoc. 1987;63:10–7.
21.
go back to reference James WG. Our precious metal: African labour in South Africa’s gold industry, 1970–1990. Cape Town: David Philip; 1992. James WG. Our precious metal: African labour in South Africa’s gold industry, 1970–1990. Cape Town: David Philip; 1992.
22.
go back to reference Crush J, Jeeves A, Yudelman D. South Africa’s labour empire: a history of black migrancy to the gold mines. Boulder: Westview Press; 1991. Crush J, Jeeves A, Yudelman D. South Africa’s labour empire: a history of black migrancy to the gold mines. Boulder: Westview Press; 1991.
23.
go back to reference Maja, B. Towards a fairer deal for migrants in the South African Economy, Labour Market Review, Department of Labour, Republic of South Africa; 2007 Maja, B. Towards a fairer deal for migrants in the South African Economy, Labour Market Review, Department of Labour, Republic of South Africa; 2007
25.
go back to reference Williams BG, MacPhail C, Campbell C, Taljaard D, Gouws E, Moema S, et al. The Carletonville-Mothusimpilo project: limiting transmission of HIV through community-based interventions. S Afr J Sci. 2000;96:351–9. Williams BG, MacPhail C, Campbell C, Taljaard D, Gouws E, Moema S, et al. The Carletonville-Mothusimpilo project: limiting transmission of HIV through community-based interventions. S Afr J Sci. 2000;96:351–9.
26.
go back to reference Williams BG, Gouws E. The epidemiology of human immunodeficiency virus in South Africa. Philos Trans R Soc Lond Ser B Biol Sci. 2001;356:1077–86.CrossRef Williams BG, Gouws E. The epidemiology of human immunodeficiency virus in South Africa. Philos Trans R Soc Lond Ser B Biol Sci. 2001;356:1077–86.CrossRef
27.
go back to reference Lurie MN, Williams BG, Zuma K, Mkaya-Mwamburi D, Garnett G, Sturm AW, et al. The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis. 2003;30:149–56.CrossRefPubMed Lurie MN, Williams BG, Zuma K, Mkaya-Mwamburi D, Garnett G, Sturm AW, et al. The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis. 2003;30:149–56.CrossRefPubMed
28.•
go back to reference Lurie MN, Williams BG. Migration and health in Southern Africa: 100 years and still circulating. Health Psychol Behav Med. 2014;2(1):34–40. Discussion of the role of migration in the spread of HIV in southern Africa. CrossRefPubMedCentralPubMed Lurie MN, Williams BG. Migration and health in Southern Africa: 100 years and still circulating. Health Psychol Behav Med. 2014;2(1):34–40. Discussion of the role of migration in the spread of HIV in southern Africa. CrossRefPubMedCentralPubMed
30.
go back to reference Hallett TB, Gregson S, Mugurungi O, Gonese E, Garnett GP. Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. Epidemics. 2009;1:108–17.CrossRefPubMed Hallett TB, Gregson S, Mugurungi O, Gonese E, Garnett GP. Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. Epidemics. 2009;1:108–17.CrossRefPubMed
31.
go back to reference Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med. 2014;12:46.CrossRefPubMedCentralPubMed Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med. 2014;12:46.CrossRefPubMedCentralPubMed
32.
go back to reference Cohen B, Trussell J (Editors) Preventing and mitigating AIDS in Sub-Saharan Africa: research and data priorities for the social and behavioral sciences (Washington, DC) (1996). Cohen B, Trussell J (Editors) Preventing and mitigating AIDS in Sub-Saharan Africa: research and data priorities for the social and behavioral sciences (Washington, DC) (1996).
33.
go back to reference Auvert B, Marseille E, Korenromp EL, Lloyd-Smith J, Sitta R, Taljaard D, et al. Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa. PLoS One. 2008;3, e2679.CrossRefPubMedCentralPubMed Auvert B, Marseille E, Korenromp EL, Lloyd-Smith J, Sitta R, Taljaard D, et al. Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa. PLoS One. 2008;3, e2679.CrossRefPubMedCentralPubMed
34.
go back to reference Batist E, Brown B, Scheibe A, Baral SD, Bekker LG. Outcomes of a community-based HIV-prevention pilot programme for township men who have sex with men in Cape Town, South Africa. J Int AIDS Soc. 2013;16 Suppl 3:18754.PubMedCentralPubMed Batist E, Brown B, Scheibe A, Baral SD, Bekker LG. Outcomes of a community-based HIV-prevention pilot programme for township men who have sex with men in Cape Town, South Africa. J Int AIDS Soc. 2013;16 Suppl 3:18754.PubMedCentralPubMed
35.
go back to reference Williams BG, Granich R, Chauhan LS, Dharmshaktu NS, Dye C. The impact of HIV/AIDS on the control of tuberculosis in India. Proc Natl Acad Sci U S A. 2005;102:9619–24.CrossRefPubMedCentralPubMed Williams BG, Granich R, Chauhan LS, Dharmshaktu NS, Dye C. The impact of HIV/AIDS on the control of tuberculosis in India. Proc Natl Acad Sci U S A. 2005;102:9619–24.CrossRefPubMedCentralPubMed
37.
38.
go back to reference Anonymous. National Antenatal Sentinel HIV and Syphilis Prevalence Survey in South Africa, 2012. Department of Health, South Africa. Available from: www.doh.gov.za (2012). Anonymous. National Antenatal Sentinel HIV and Syphilis Prevalence Survey in South Africa, 2012. Department of Health, South Africa. Available from: www.​doh.​gov.​za (2012).
39.
go back to reference Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS. 2014;28:2439–49.CrossRefPubMedCentralPubMed Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS. 2014;28:2439–49.CrossRefPubMedCentralPubMed
40.
go back to reference Kim AA, Hallett T, Stover J, Gouws E, Musinguzi J, Mureithi PK, et al. Estimating HIV incidence among adults in Kenya and Uganda: a systematic comparison of multiple methods. PLoS One. 2011;6, e17535.CrossRefPubMedCentralPubMed Kim AA, Hallett T, Stover J, Gouws E, Musinguzi J, Mureithi PK, et al. Estimating HIV incidence among adults in Kenya and Uganda: a systematic comparison of multiple methods. PLoS One. 2011;6, e17535.CrossRefPubMedCentralPubMed
42.
go back to reference UNAIDS. Regional consultation to set new targets for the HIV response post-2015 in Eastern and Southern Africa. Johannesburg; 19–20 May 2014. Available from: www.unaidsrstesa.org (2014). UNAIDS. Regional consultation to set new targets for the HIV response post-2015 in Eastern and Southern Africa. Johannesburg; 19–20 May 2014. Available from: www.​unaidsrstesa.​org (2014).
43.
go back to reference Williams BG, Korenromp EL, Gouws E, Schmid GP, Auvert B, Dye C. HIV Infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis. 2006;194:1450–8.CrossRefPubMed Williams BG, Korenromp EL, Gouws E, Schmid GP, Auvert B, Dye C. HIV Infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis. 2006;194:1450–8.CrossRefPubMed
45.
go back to reference Ministerio da Saude SNdS. Relatório Semestral das Actividades Relacionadas ao HIV/SIDA. Moçambique. 2014. Maputo. Ministerio da Saude SNdS. Relatório Semestral das Actividades Relacionadas ao HIV/SIDA. Moçambique. 2014. Maputo.
47.
go back to reference Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12:607–14.CrossRefPubMed Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12:607–14.CrossRefPubMed
48.
go back to reference Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr Hum Retrovirol. 2007;45:183–92.CrossRef Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr Hum Retrovirol. 2007;45:183–92.CrossRef
49.
go back to reference Antoniou T, Gillis J, Loutfy MR, Cooper C, Hogg RS, Klein MB, et al. Impact of the data collection on adverse events of anti-HIV drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada. J Int Assoc Provid AIDS Care. 2014;13:153–9.CrossRefPubMed Antoniou T, Gillis J, Loutfy MR, Cooper C, Hogg RS, Klein MB, et al. Impact of the data collection on adverse events of anti-HIV drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada. J Int Assoc Provid AIDS Care. 2014;13:153–9.CrossRefPubMed
50.
go back to reference Williams BG, Maher D. Tuberculosis fuelled by HIV: putting out the flames. Am J Respir Crit Care Med. 2007;175:6–8.CrossRefPubMed Williams BG, Maher D. Tuberculosis fuelled by HIV: putting out the flames. Am J Respir Crit Care Med. 2007;175:6–8.CrossRefPubMed
Metadata
Title
Epidemiological Trends for HIV in Southern Africa: Implications for Reaching the Elimination Targets
Authors
Brian G. Williams
Eleanor Gouws
Pierre Somse
Mpho Mmelesi
Chibwe Lwamba
Trouble Chikoko
Erika Fazito
Mohamed Turay
Eva Kiwango
Pepukai Chikukwa
Henry Damisoni
Michael Gboun
Publication date
01-06-2015
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 2/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-015-0264-x

Other articles of this Issue 2/2015

Current HIV/AIDS Reports 2/2015 Go to the issue

Central Nervous System and Cognition (SS Spudich, Section Editor)

Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy

Central Nervous System and Cognition (SS Spudich, Section Editor)

Novel Neuroimaging Methods to Understand How HIV Affects the Brain

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine